FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
11. April 2024 07:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experienceDr. Beher...
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
20. März 2024 02:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative...
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
07. Februar 2024 08:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
17. November 2022 07:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant Heidelberg, Germany – 17 November 2022...